is semaglutide under patent Ozempic's problem: how Novo Nordisk lost control of a blockbuster drug. ๐ Demand for GLP-1 weight-loss drugs has exploded, turning Ozempic into a $40bn+ revenue engine for Novo Nordisk. But, despite Novo Nordisk patent expiry opens
Description
Interview Courtesy | Ankit Kankar #GLP1 #Diabetes #Obesity #Cardiology #Metabolism #Therapeutics #Innovation #Healthcare #Medicine #Research #Pharmacology #Biotechnology #Clinicaltrials #Prevention #Wellness
Mochi Health is a telehealth company based in San Francisco that connects patients with licensed providers for weight loss treatment.......
Not research-grade powder
We Launched Noom GLP-1RX Because Pairing Powerful, High-Quality Compounded Meds with Powerful Lifestyle Change is in the Public Interest.
)
I'm sharing my personal go-to list
